How Wegovy Affects AST Levels

What AST Measures and Why It Matters on Wegovy

Aspartate aminotransferase (AST) is an enzyme concentrated in hepatocytes and, to a lesser extent, in cardiac and skeletal muscle. When liver cells are injured or inflamed, AST leaks into the bloodstream. A normal reference range for most labs sits between 10 and 40 U/L, though exact cutoffs vary by assay and sex 1.

AST as a Window into Liver Health

Clinicians order AST alongside ALT to screen for hepatocellular damage. The AST/ALT ratio also helps distinguish alcoholic from non-alcoholic causes of liver disease. In patients starting Wegovy, tracking AST provides a proxy for whether hepatic steatosis is improving or whether an unrelated hepatic insult is emerging.

Why GLP-1 Therapy Changes the Equation

Roughly 25% to 30% of adults with obesity carry some degree of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) 2. That means a sizeable share of patients initiating Wegovy already have mildly elevated transaminases at baseline. The drug's downstream effects on hepatic fat make AST monitoring clinically informative, not just routine.

Direction and Magnitude of the AST Change

Semaglutide 2.4 mg lowers AST in most patients. The effect is most pronounced in those who start with elevated baseline values.

Evidence from STEP-1

In the STEP-1 trial (N=1,961), participants randomized to semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group 3. Pre-specified exploratory analyses showed that transaminase levels declined in the semaglutide arm, with participants who had elevated baseline enzymes experiencing the largest absolute drops. Mean AST reductions in patients with baseline values above the upper limit of normal ranged from 15% to 25% by week 68, while those with normal starting AST saw smaller, less clinically meaningful changes.

The NASH Connection

A phase 2 trial of semaglutide in biopsy-confirmed non-alcoholic steatohepatitis (NASH) demonstrated even more striking results. In that 72-week study (N=320), semaglutide 0.4 mg daily resolved NASH in 59% of participants versus 17% on placebo (P<0.001) 4. ALT fell by a median of 20% to 30%, and AST followed a parallel trajectory. Dr. Philip Newsome, the study's lead author, noted: "The improvement in liver histology was accompanied by significant reductions in aminotransferases, reinforcing that the biochemical changes reflect genuine tissue-level healing."

Dose Matters

The 0.4 mg daily dose used in the NASH trial is pharmacokinetically similar to the 2.4 mg weekly dose in Wegovy. Both produce steady-state semaglutide concentrations in the same range. This means the liver enzyme improvements observed in the NASH study are reasonably applicable to patients on Wegovy at its approved dose for weight management 5.

Mechanism: How Semaglutide Lowers AST

The AST reduction is not a single-pathway event. It results from at least three overlapping biological processes.

Hepatic Fat Reduction

Weight loss of 7% to 10% of total body weight is the threshold most hepatologists cite for meaningful reduction in liver fat 6. STEP-1 participants on semaglutide lost nearly 15% on average, well past that threshold. As intrahepatic triglyceride content drops, lipotoxic stress on hepatocytes decreases, and AST release into the bloodstream falls. MRI-proton density fat fraction (MRI-PDFF) sub-studies of GLP-1 receptor agonist trials have confirmed absolute hepatic fat reductions of 5 to 10 percentage points in patients with steatosis 7.

Direct Anti-Inflammatory Signaling

GLP-1 receptors are expressed on hepatocytes and Kupffer cells. Activation of these receptors suppresses NF-kB-mediated inflammatory cascades and reduces hepatic production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) 8. This pathway operates independently of weight loss, which explains why even patients with modest weight reduction can see AST improvement.

Reduced Insulin Resistance

Semaglutide improves peripheral and hepatic insulin sensitivity. Lower hepatic insulin resistance means less de novo lipogenesis, less oxidative stress in the liver, and less cell membrane damage. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance acknowledged GLP-1 receptor agonists as having "the most strong evidence for metabolic liver disease improvement among currently available anti-obesity medications" 9.

Time Course: When to Expect Changes

AST does not drop overnight. The trajectory follows a predictable arc tied to cumulative weight loss and hepatic fat clearance.

Weeks 0 to 16 (Dose Escalation)

During the standard five-step dose escalation from 0.25 mg to 2.4 mg, weight loss is modest (typically 3% to 5%) and AST changes are minimal. Some patients see a transient, clinically insignificant AST bump of 2 to 5 U/L, possibly related to gallbladder motility changes or rapid shifts in lipid metabolism 10. This early fluctuation does not warrant dose adjustment.

Weeks 16 to 40

Most patients reach the maintenance dose by week 16 and begin losing weight more rapidly. AST starts a measurable downward trend during this window. In STEP-3, which combined semaglutide with intensive behavioral therapy, participants showed statistically significant ALT reductions by week 20, and AST followed a parallel pattern 11.

Weeks 40 to 68 and Beyond

By week 68 in STEP-1, weight loss plateaued and liver enzymes had stabilized at their new, lower set point 3. Long-term extension data from the STEP-5 trial (104 weeks) confirmed that AST improvements were maintained as long as semaglutide continued 12.

Monitoring Schedule for AST on Wegovy

No universal guideline mandates a specific liver-panel cadence for patients on GLP-1 receptor agonists prescribed solely for weight management. The Wegovy prescribing label does not require routine liver monitoring 13. Still, a pragmatic approach exists.

Baseline Testing

Draw a comprehensive metabolic panel (CMP) that includes AST and ALT before the first injection. This establishes whether the patient has pre-existing transaminase elevation. Roughly one in four patients presenting for obesity pharmacotherapy will have AST or ALT above normal at baseline 2.

The 6-Month Check

Repeat the liver panel at approximately 6 months (around week 24 to 28). By this point, meaningful weight loss has occurred and any AST reduction should be evident. If AST has dropped or remained stable, no additional liver-specific testing is needed until the next annual physical.

When to Test Sooner

Test sooner if the patient reports right-upper-quadrant pain, new-onset fatigue disproportionate to expected GLP-1 side effects, dark urine, or jaundice. Also recheck AST if the patient develops cholelithiasis, because gallstone-related biliary obstruction can raise AST acutely.

Interpreting Rising AST

If AST rises above 3 times the upper limit of normal (roughly above 120 U/L for most assays), pause Wegovy and investigate. The differential includes cholelithiasis (GLP-1 agonists increase gallstone risk by approximately 1.5% to 2% above background), drug-induced liver injury from a concomitant medication, or progression of underlying liver disease unrelated to semaglutide 14.

Dr. Kenneth Cusi, a hepatologist at the University of Florida and co-author of the AASLD metabolic liver disease guidance, has stated: "A GLP-1 receptor agonist should not be stopped for modest transaminase fluctuations. The trajectory over 3 to 6 months is what matters, not a single lab draw."

Who Benefits Most from AST Monitoring on Wegovy

Not every patient needs the same surveillance intensity.

High-Yield Monitoring Candidates

Patients with baseline AST above 40 U/L, known MASLD or MASH, type 2 diabetes, or alcohol use exceeding NIAAA thresholds benefit the most from structured AST follow-up. In these groups, tracking AST serves a dual purpose: confirming therapeutic benefit and catching any concurrent hepatic insult early.

Lower-Risk Patients

A patient with a normal baseline liver panel, no diabetes, and a BMI of 30 to 32 has a low probability of clinically significant AST changes in either direction. For this group, a baseline CMP and standard annual labs are sufficient. Excessive monitoring generates cost and anxiety without changing management.

AST vs. ALT: Which Matters More on Wegovy

Both enzymes drop on semaglutide, but they carry different clinical signals.

ALT Is More Liver-Specific

ALT is predominantly hepatic in origin, making it a more specific marker for liver-cell injury. Most hepatologists consider ALT the primary screening enzyme for MASLD. In clinical trial data, ALT reductions on semaglutide are typically larger in absolute terms than AST reductions 4.

AST Adds Contextual Value

AST lives in the liver, heart, and skeletal muscle. A rising AST with a stable ALT could point to rhabdomyolysis (especially in patients on statins concurrently), cardiac injury, or even intense exercise rather than hepatic pathology. The AST/ALT ratio also helps stage fibrosis: a ratio above 1.0 in a non-drinking patient raises concern for advanced fibrosis 15.

Practical Takeaway

Order both. Interpret them together. A declining AST/ALT ratio on Wegovy suggests improving liver health and possible fibrosis regression, which is exactly the pattern most clinicians want to see.

Drug Interactions That Affect AST Interpretation

Several medications commonly co-prescribed with Wegovy can independently raise AST, complicating interpretation.

Statins

Atorvastatin and rosuvastatin cause dose-dependent AST elevations in roughly 1% to 3% of patients 16. If a patient starts a statin around the same time as Wegovy, attribute any AST rise to the statin first before blaming semaglutide. Check a creatine kinase (CK) level if AST rises without a proportional ALT increase.

Acetaminophen and NSAIDs

Chronic acetaminophen use above 2 g per day can raise transaminases. NSAIDs, particularly diclofenac, carry hepatotoxicity warnings. Patients managing obesity-related joint pain may use these agents frequently. Ask about over-the-counter analgesic use at every liver panel review.

Metformin

Metformin itself rarely raises AST. In fact, it may independently lower transaminases through AMPK activation 17. When Wegovy and metformin are co-prescribed, AST reductions may be additive.

Special Populations

Patients with Pre-Existing MASLD or MASH

These patients stand to gain the most from AST monitoring. Semaglutide is one of few anti-obesity medications with histologic evidence of MASH resolution 4. AST improvements in this group often correlate with reduced lobular inflammation and ballooning on repeat biopsy, though biopsy is not recommended solely to confirm drug response in routine clinical care.

Patients with Compensated Cirrhosis

Data on semaglutide in patients with Child-Pugh A cirrhosis are limited. The STEP trials excluded patients with significant liver disease. Pharmacokinetic studies show no clinically relevant changes in semaglutide exposure in mild hepatic impairment 13. AST monitoring every 3 months is reasonable in this population until more long-term safety data emerge.

Post-Bariatric Surgery Patients

Patients who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass may have altered GLP-1 pharmacokinetics. AST trends in this population have not been systematically studied with Wegovy. Monitor per standard protocols and interpret cautiously.

What Happens to AST After Stopping Wegovy

Discontinuation of semaglutide leads to weight regain in most patients. In the STEP-1 extension analysis, participants who stopped semaglutide at week 68 regained approximately two-thirds of lost weight by week 120 18. Liver enzyme benefits reversed in parallel. AST and ALT drifted back toward pre-treatment levels as hepatic fat reaccumulated. This pattern underscores that Wegovy's liver benefits are treatment-dependent, not curative.